Liquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Received tentative approval from the FDA for YUTREPIA (treprostinil) inhalation powder for both pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)U.S. Supreme Court rejected final appeal of ‘793 patent decision,… Read More »Liquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate Update


